De su propio informe. Pero, efectivamente, considerando el efecto de los warrants:
THRESHOLD PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(Unaudited)
Three Months Ended
March 31,
-------------------
2012 2011
--------- ---------
Revenue $ 252 $ -
Operating expenses
Research and development 5,687 6,097
General and administrative 1,708 1,297
--------- ---------
Total Operating Expenses 7,395 7,394
Loss from operations (7,143) (7,394)
Interest income (expense), net 1 3
Other Income (expense), net (1) (108,391) (939)
--------- ---------
Net Loss (115,533) (8,330)
========= =========
Net loss per common share-basic and diluted $ (2.30)$ (0.23)
========= =========
Weighted-average shares used in computing basic and
diluted net loss per common share 50,326 36,445
========= =========
(1) Non-cash expense related to the change in fair value of the Company's
outstandingand exercised warrants, classified as other income (expense).
Y NO ME DIGAS QUE CON EL P... CONCORDE TE SALEN 4,34 QUE ¡LE PRENDO FUEGO!, COMO AL ÚLTIMO... :D
S2
Sorry, al pegar se va el formato a la m... el vínculo es el que ha puesto R2d2 c3po: http://finance.yahoo.com/news/threshold-pharmaceuticals-reports-first-quarter-202700653.html